Sensei Biotherapeutics, Inc. Common Stock
SNSENASDAQUS Equity
$13.85▼ $3.09 (−22.28%)
Live1h—
24h▼ 22.3%
7d▼ 0.4%
14d▼ 0.4%
30d▼ 0.4%
1y▲ 80.6%
🏦Market Cap
$211B
Large Cap
📈Revenue Growth (YoY)
+32.9%
High Growth
📊Gross Margin
43.6%
Healthy
💵FCF Margin
23.7%
Strong
⚖️P/S Ratio
12.9x
Elevated
Otter Score
59
Weak
Trading Snapshot
- Day Range
- $13.71 – $14.02
- 52-Week Range
- $792.72 – $1,368.74
- Volume
- $2.53B
- Avg Volume
- $2.03B
- Shares Outstanding
- 15.24B
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $16.36B
- Last Q Revenue
- $3.68B
- P/E Ratio
- 30.6
- P/S Ratio
- 12.9x
- EPS (TTM)
- $31.86
- Dividend Yield
- 1.31%
Why Investors Own SNSE
- ✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 44% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$16.36B▲ +38.1% YoY
Gross Margin (TTM)
43.6%▲ +3.3% YoY
Operating Income (TTM)
$3.94B▲ +38.1% YoY
Free Cash Flow (TTM)
$3.88B▲ +38.1% YoY
About Sensei Biotherapeutics, Inc. Common Stock
A company profile for Sensei Biotherapeutics, Inc. Common Stock isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
59/100
Analyst Price Target
ⓘAverage Target
$15.00
▲ +8.3% Upside
High Target$18.69
Low Target$12.16
Based on 36 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
Sensei Biotherapeutics, Inc. Common Stock tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift SNSE price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
Sensei Biotherapeutics, Inc. Common Stock announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.